Clinical Trials

A RANDOMIZED PHASE II/III OPEN-LABEL STUDY OF IPILIMUMAB AND NIVOLUMAB VERSUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MGMT (TUMOR O-6-METHYLGUANINE DNA METHYLTRANSFERASE) UNMETHYLATED GLIOBLASTOMA


Study ID
NRG-BN007

NCT Number
NCT04396860 (Click on the NCT number for more information about the trial)

Research Study Number
2020-0864

Principle Investigator
Dr. Goldlust, Samuel

Phase
II/III

Sponsor
NRG Oncology


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now